ArticleArchives of Razi Institute2025
Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis of
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Materials & Methods: In this bioinformatics study, we employed a range of tools to predict the fundamental characteristics of the ROP13 protein. Results: Our analysis revealed that the ROP13 protein consists of 400 amino acid residues with an average molecular weight (MW) of 44,714.15 daltons. The grand average of hydropathicity (GRAVY) was determined to be -0.311, indicating the protein's hydrophilic nature, while the aliphatic index scored 84.40, highlighting its hydrophobic character. Furthermore, we identified 43 post-translationally modified sites within the ROP13 sequence. When examining the secondary structure, the ROP13 protein was predicted to have a composition of 40% alpha helix, 9.25% extended strand, and 50.75% random coil using the GOR4 method, suggesting a diverse structural organization that may contribute to its functional versatility. Additionally, our analysis identified several potential B- and T-cell epitopes within the ROP13 sequence, indicating regions that could be targeted for immune responses. Conclusion: The bioinformatics analysis of ROP13 provides valuable insights into its structural, immunogenic, and antigenic properties, highlighting its potential as a target for vaccine development against toxoplasmosis. By leveraging the predicted characteristics of ROP13, researchers can explore various vaccine strategies to enhance host immunity and combat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.